Evidence map›Paper›PMID 24375205›Full record

Observational studyThe Journal of nervous and mental disease2014

Community adherence to schizophrenia treatment and safety monitoring guidelines.

William R Keller, Bernard A Fischer, Robert McMahon, Walter Meyer, Melissa Blake, Robert W Buchanan

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The Journal of nervous and mental disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Lack of tolerable treatment options for patients with schizophrenia.Neuropsychiatric disease and treatment · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

William R Keller*Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; and †VA Capital Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, MD.
Bernard A Fischer
Robert McMahon
Walter Meyer
Melissa Blake
Robert W Buchanan
University of Maryland, Baltimore · US

Funding

CORE--RESEARCH NETWORK DEVELOPMENT COREP30MH068580 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI BUCHANAN, ROBERT W · 2003 to 2007
$7.9M
Multidisciplinary Schizophrenia Research TrainingT32MH067533 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CARPENTER, WILLIAM T., ELMER, GREGORY I · 2004 to 2025
$4.3M
NIMH NIH HHS P30 MH068580NIMH NIH HHS P30MH068580NIMH NIH HHS T32 MH067533NIMH NIH HHS T32MH067533
6 · The paper itself

Abstract

The 2003 Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations and the Mount Sinai Conference Safety Monitoring recommendations generated guidelines for pharmacological treatment of schizophrenia and monitoring of antipsychotic side effects. This study examined rate of recommendation adherence and impact of adherence on outcomes of outpatients with schizophrenia or schizoaffective disorder in community mental health centers. Clinical practice was assessed as conformant, nonconformant, or not applicable. Treatment practices were conformant for antipsychotic dose (83%); use of antiparkinsonian (97%), antidepressant (100%), and antianxiety agents (90%) but not clozapine for residual positive symptoms (31%); and monitoring weight gain (48%), glucose dysregulation (53%), hyperlipidemia (34%), or extrapyramidal symptoms (11%). Community mental health center treatment practices were largely conformant with the 2003 Schizophrenia PORT treatment recommendations. There is less evidence that patients who receive treatment in the community are adequately monitored for antipsychotic side effects per the Mount Sinai recommendations.

Indexed as

Medication AdherenceAdultAgedAnti-Anxiety AgentsAntidepressive AgentsAntiparkinson AgentsAntipsychotic AgentsBlood GlucoseCross-Sectional StudiesDrug MonitoringFemaleGuideline AdherenceHumansHyperlipidemiasMaleMiddle AgedAnti-Anxiety AgentsAntidepressive AgentsAntiparkinson AgentsAntipsychotic AgentsBlood Glucose

Identifiers

PMID24375205
PMCPMC4228984
OpenAlexW2044292883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.